[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

La Merie Publishing: Market Research Reports

Set up in 2002, La Merie Publishing is an authoritative supplier of the cutting-edge information on the biopharmaceutical industry, with a special focus on the research and development pipeline and covering issues related to biologics, including peptides, antibodies, DNA, RNA, proteins and cell therapy.

The company’s service portfolio is represented by various formats and price levels, and includes Brief Reports, Full Reports and Competitor Analysis Reports. Competitor Analysis Reports present no frills, but accurate data on the pipeline of research and development projects for diseases, targets, companies and technologies. The data are fully referenced and delivered in a tabular format. Brief Reports covering Target Pipelines contain all-round assessments of both business and scientific perspectives of new targets. Full Reports present deep analyses of product portfolios, competitive landscape, R&D pipelines and discussions of the pipeline perspectives.

Publications found: 223
Sort by:
Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates US$ 225.00

Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This ... for Antibody-Drug Conjugates. Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 ...

October 2016 22 pages
CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies US$ 225.00

CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies. Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics ...

October 2016 20 pages
CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells US$ 225.00

CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells ... TCR & CAR T-Cells and NK Cells Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile ...

October 2016 25 pages
Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016 US$ 225.00

Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016 This Competitive Intelligence report about NGF-TrkA Pathway Agonists & Antagonist provides a competitor evaluation in the field of recombinant antibodies, proteins and small molecules acting as antagonists or agonists of NGF or its high affinity receptor TrkA ...

October 2016 27 pages
Competitor Analysis Immunotoxins 2016 US$ 225.00

Competitor Analysis Immunotoxins 2016 This Competitive Intelligence report about Immunotoxins provides a competitor evaluation in the field of recombinant fusion proteins of a mainly antibody-based ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

September 2016 31 pages
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs US$ 2,626.00

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs The report TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies ... ; Engineered TCR T-cells, including TCR target discovery; The current status of DLIs, CTLs and TILs; Manufacturing of T-cells for adoptive cell therapy; NK cells and CAR engineered NK cells; International perspective on TCR & CAR T-cell and NK cell ...

August 2016 388 pages
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities US$ 570.00

... Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target ...

August 2016 39 pages
CD123: a paradigmatic target for immunotherapeutic treatment modalities US$ 800.00

CD123: a paradigmatic target for immunotherapeutic treatment modalities This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the ... -CD123 Immunotherapeutics Clinical Experience with CD123-Targeted Treatment Modalities Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics Competitive Landscape Profiles of Anti-CD123 Immunotherapeutics ...

August 2016 83 pages
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases US$ 560.00

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive ... as: T-Cell or NK cell redirecting bispecific cancer antibodies Bispecific immuno-oncology antibodies Bispecific tumor antigens targeted cancer antibodies Bispecific antibodies for inflammatory autoimmune diseases Bispecific antibodies for cardiometabolic, infectious, neurologic ...

June 2016 180 pages
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016 US$ 225.00

Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016 This Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules ... for prevention and  treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular ...

June 2016 34 pages
T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals US$ 2,197.00

... T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. This report T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals “ as of May 2016 brings you up-to-date information ...

May 2016 230 pages
Сompetitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,450.00

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ...

May 2016 462 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May 2016 74 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update US$ 280.00

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May 2016 56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May 2016 84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update US$ 560.00

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May 2016 124 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,393.00

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

May 2016 462 pages
Antibody Target, Technology & Pipeline Database: 1-Year Subscription US$ 1,600.00

Antibody Target, Technology & Pipeline Database: 1-Year Subscription Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached ... of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the Antibody Pipeline Database: Intuitive ...

April 2016
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update US$ 350.00

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment ... T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism ...

April 2016 74 pages
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists US$ 1,018.00

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target ... from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects ...

February 2016 88 pages
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update US$ 440.00

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

February 2016 46 pages
Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals US$ 220.00

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more ... Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor ...

February 2016 42 pages
Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines US$ 330.00

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines The Competitive Intelligence Report Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines“ provides a competitor ...

February 2016 39 pages
Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors US$ 220.00

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

February 2016 32 pages
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family US$ 225.00

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline ...

January 2016 28 pages
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis US$ 2,519.00

... same number of ADC programs are in preclinical R&D. Download Samples Pages: Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis For the first ... entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles ...

November 2015 470 pages
Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines US$ 345.00

Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the ... , the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information ...

September 2015 44 pages
Competitor Analysis: Interleukin-4/-13 (IL-4/-13) Inhibitors or Receptor Antagonists US$ 115.00

Competitor Analysis: Interleukin-4/-13 (IL-4/-13) Inhibitors or Receptor Antagonists The Competitive Intelligence report about inhibitors of interleukin-4 (IL-4) and/or IL-13 and antagonists of the IL-4 or IL-13 receptor provides a competitor analysis of novel antibody molecules for treatment ...

September 2015 15 pages
Competitor Analysis: Sphingosine-1-Phosphate (S1P) Receptor Modulators US$ 115.00

Competitor Analysis: Sphingosine-1-Phosphate (S1P) Receptor Modulators The Competitive Intelligence report about sphingosine-1-phosphate (S1P) receptor modulators provides a competitor analysis of approved or novel S1P receptor modulators for treatment of inflammatory and autoimmune diseases such ...

September 2015 15 pages
Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists US$ 115.00

Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

September 2015 16 pages
Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists US$ 170.00

Competitor Analysis: Interleukin-17/Receptor (IL-17/R) Antagonists The Competitive Intelligence report about Interleukin-17 (IL-17) inhibitors and IL-17 receptor IL-17R) antagonists provides a competitor analysis as of August 2015 in the development pipeline of novel inhibitors and antagonists of IL-17 and ...

August 2015 20 pages
Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis US$ 460.00

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

July 2015 76 pages
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors US$ 1,500.00

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

April 2015 414 pages
Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux US$ 288.00

Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015 ...

March 2015 50 pages
Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab US$ 346.00

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated ...

March 2015 62 pages
Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel US$ 577.00

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha ...

March 2015 107 pages
2014 Sales of Recombinant Therapeutic Antibodies & Proteins US$ 140.00

2014 Sales of Recombinant Therapeutic Antibodies & Proteins This Competitive Intelligence report prepared by La Merie Business Intelligence provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2014. Sales data were obtained from company publications ...

March 2015 39 pages
Engineered TCR and CAR Immunotherapeutics 2015 US$ 2,630.00

... Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs The engineered ... Cellular TCR T Cells CAR T Cells (autologous/allogeneic) Recombinant Bispecific TCR-anti-CD3 (e.g. ImmTACs) Bispecific antibodies (incl. anti-CD3) This report Engineered TCR and CAR Immunotherapeutics ...

March 2015 201 pages
Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators US$ 185.00

... Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and ...

March 2015 18 pages
Competitor Analysis: Specific and Bispecific Her3 Antibodies US$ 260.00

Competitor Analysis: Specific and Bispecific Her3 Antibodies This Competitive Intelligence Report about Specific and Bispecific Her3 Antibodies provides a competitor evaluation in the field of recombinant specific antibodies targeting Her3 or bispecific antibodies targeting Her3 and Her2 or EGF-R or other ...

February 2015 27 pages
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin US$ 390.00

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

February 2015 64 pages
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis US$ 460.00

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

February 2015 79 pages
Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease US$ 260.00

... Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease The Competitive Intelligence report about Alpha ... on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed ...

January 2015 32 pages
Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates US$ 260.00

Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf ...

January 2015 25 pages
Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants US$ 2,795.00

Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants A Pipeline ... coagulation factors Corporate profiles of all relevant stakeholders including deals and pipelines Pipeline and technology trends Download Sample Pages: Recombinant Coagulation Factors 2015 - Maturation of recombinant clotting factor pipeline ...

December 2014 210 pages
Peptide Therapeutics Pipeline Database: 1-Year Subscription US$ 1,000.00

Peptide Therapeutics Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files. Each ...

November 2014
Competitor Analysis: Cancer Peptides US$ 500.00

Competitor Analysis: Cancer Peptides The Competitive Intelligence Report Cancer Peptides as of November 2014 provides a competitor analysis in the product portfolios and development pipeline of peptide therapeutics for treatment of cancer. Purchase of the pdf report includes a 6-month online access to the ...

November 2014 99 pages
Competitor Analysis: Cardiometabolic Peptides US$ 500.00

Competitor Analysis: Cardiometabolic Peptides The Competitive Intelligence Report Cardiometabolic Peptides as of November 2014 provides a competitor analysis in the development pipeline of peptide therapeutics for treatment of diabetes, obesity and atherosclerosis. Purchase of the pdf report includes a 6- ...

November 2014 77 pages
Competitor Analysis: Ebola Virus Vaccines and Therapeutics US$ 255.00

Competitor Analysis: Ebola Virus Vaccines and Therapeutics The present Competitive Intelligence Report about prophylaxis and therapy of Ebola virus infections ... Ebola virus infections as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any ...

October 2014 43 pages
Competitor Analysis: Anti-Infective Peptides US$ 446.00

Competitor Analysis: Anti-Infective Peptides The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and ... with the project data to print or export an individual report. Anti-Bacterial Peptides Anti-bacterial peptides are used to treat infectious diseases such ...

October 2014 68 pages

Filters

Search

Categories

2
1
1
4
1
19
27
3
2
1
10
4
21
5
5
100
17

Publishers

223

Regions

223

Price

Date

Pages

Offers

1
4